Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia

Biotechnology Advances

Volumn 32, Issue 8, 2014, Pages 1396-1409

  Guo, Jianfeng ^a   Cahill, Mary R ^b   McKenna, Sharon L ^c   O'Driscoll, Caitriona M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Leukaemia; Non viral nanoparticles; SiRNA delivery

Indexed keywords

AMINO ACIDS; BIOMIMETICS; BONE; CHEMOTHERAPY; DISEASES; GENES; ONCOGENIC VIRUSES; RNA; STEM CELLS;

CHRONIC MYELOID LEUKAEMIA; LEUKAEMIA; MULTI-FUNCTIONAL NANOPARTICLES; NONVIRAL; PHYSIOLOGICAL ENVIRONMENT; SIRNA DELIVERY; SMALL INTERFERING RNA (SIRNA); TYROSINE KINASE INHIBITOR;

NANOPARTICLES;

CANCER; GENE EXPRESSION; MOLECULAR ANALYSIS; PARTICLE SIZE; PATHOGENICITY; PHYSIOLOGY; RNA; SURVIVAL;

ANTINEOPLASTIC AGENT; BIOMIMETIC MATERIAL; NANOPARTICLE; SMALL INTERFERING RNA;

ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; GENETICS; HUMAN; LEUKEMIA; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMIMETIC MATERIALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA; NANOPARTICLES; RNA, SMALL INTERFERING;

EID: 84912107533     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2014.08.007     Document Type: Review

References (141)

1. Awasthi V.D., Garcia D., Goins B.A., Phillips W.T. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int J Pharm 2003, 253:121-132.
2. Bankston P.W., De Bruyn P.P. The permeability to carbon of the sinusoidal lining cells of the embryonic rat liver and rat bone marrow. Am J Anat 1974, 141:281-285.
3. Bissels U., Bosio A., Wagner W. MicroRNAs are shaping the hematopoietic landscape. Haematologica 2012, 97:160-167.
4. Bohlander S.K. Chromosomal translocations in leukaemia: emerging networks. Chromosomes Today 2004, 14:157-168. Springer. M. Schmid, I. Nanda (Eds.).
5. Borkhardt A., Heidenreich O. RNA interference as a potential tool in the treatment of leukaemia. Expert Opin Biol Ther 2004, 4:1921-1929.
6. Bratkovic T., Glavan G., Strukelj B., Zivin M., Rogelj B. Exploiting microRNAs for cell engineering and therapy. Biotechnol Adv 2012, 30:753-765.
7. Chan E., Prado D.E., Weidhaas J.B. Cancer microRNAs: from subtype profiling to predictors of response to therapy. Trends Mol Med 2011, 17:235-243.
8. Chen Z.G. Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med 2010, 16:594-602.
9. Chen J., Wall N.R., Kocher K., Duclos N., Fabbro D., Neuberg D., et al. Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J Clin Invest 2004, 113:1784-1791.
10. Chen W.H., Xu X.D., Jia H.Z., Lei Q., Luo G.F., Cheng S.X., et al. Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo. Biomaterials 2013, 34:8798-8807.
11. Chen N., Wei M., Sun Y., Li F., Pei H., Li X., et al. Self-assembly of poly-adenine-tailed CpG oligonucleotide-gold nanoparticle nanoconjugates with immunostimulatory activity. Small 2014, 10:368-375.
12. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty Ipe B., et al. Renal clearance of quantum dots. Nat Biotechnol 2007, 25:1165-1170.
13. Choi K.M., Kwon I.C., Ahn H.J. Self-assembled amphiphilic DNA-cholesterol/DNA-peptide hybrid duplexes with liposome-like structure for doxorubicin delivery. Biomaterials 2013, 34:4183-4190.
14. Cohen-Haguenauer O. A comprehensive resource on EU regulatory information for investigators in gene therapy clinical research and advanced therapy medicinal products. Hum Gene Ther 2013, 24:12-18.
15. Dassie J.P., Liu X.Y., Thomas G.S., Whitaker R.M., Thiel K.W., Stockdale K.R., et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009, 27:839-849.
16. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
17. de Boer J., Walf-Vorderwulbecke V., Williams O. In focus: MLL-rearranged leukemia. Leukemia 2013, 27:1224-1228.
18. Decuzzi P., Ferrari M. Modulating cellular adhesion through nanotopography. Biomaterials 2010, 21:173-179.
19. Dominska M., Dykxhoorn D.M. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 2010, 123:1183-1189.
20. Du J.Z., Mao C.Q., Yuan Y.Y., Yang X.Z., Wang J. Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy. Biotechnol Adv 2014, 32:789-803.
21. Eguchi A., Meade B.R., Chang Y.C., Fredrickson C.T., Willert K., Puri N., et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 2009, 27:567-571.
22. Faderl S., Kantarjian H. Leukemias: principles and practice of therapy 2011, John Wiley & Sons.
23. Fatemian T., Othman I., Chowdhury E.H. Strategies and validation for siRNA-based therapeutics for the reversal of multi-drug resistance in cancer. Drug Discov Today 2014, 19:71-78.
24. Fazzina R., Lombardini L., Mezzanotte L., Roda A., Hrelia P., Pession A., et al. Generation and characterization of bioluminescent xenograft mouse models of MLL-related acute leukemias and in vivo evaluation of luciferase-targeting siRNA nanoparticles. Int J Oncol 2012, 41:621-628.
25. Fellmann C., Lowe S.W. Stable RNA interference rules for silencing. Nat Cell Biol 2014, 16:10-18.
26. Ford A.M., Palmi C., Bueno C., Hong D., Cardus P., Knight D., et al. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest 2009, 119:826-836.
27. Francia G., Kerbel R.S. Raising the bar for cancer therapy models. Nat Biotechnol 2010, 28:561-562.
28. Frenette P.S., Subbarao S., Mazo I.B., von Andrian U.H., Wagner D.D. Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow. Proc Natl Acad Sci U S A 1998, 95:14423-14428.
29. Gao Y., Xie J., Chen H., Gu S., Zhao R., Shao J., et al. Nanotechnology-based intelligent drug design for cancer metastasis treatment. Biotechnol Adv 2014, 32:761-777.
30. Gerber D.E. Targeted therapies: a new generation of cancer treatments. Am Fam Physician 2008, 77:311-319.
31. Gilleron J., Querbes W., Zeigerer A., Borodovsky A., Marsico G., Schubert U., et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 2013, 31:638-646.
32. Godinho B.M., McCarthy D.J., Torres-Fuentes C., Beltran C.J., McCarthy J., Quinlan A., et al. Differential nanotoxicological and neuroinflammatory liabilities of non-viral vectors for RNA interference in the central nervous system. Biomaterials 2014, 35:489-499.
33. Grimm D., Kay M.A. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?. J Clin Invest 2007, 117:3633-3641.
34. Guo S., Huang L. Nanoparticles containing insoluble drug for cancer therapy. Biotechnol Adv 2014, 32:778-788.
35. Guo J., Fisher K.A., Darcy R., Cryan J.F., O'Driscoll C. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Mol Biosyst 2010, 6:1143-1161.
36. Guo J., Bourre L., Soden D.M., O'Sullivan G.C., O'Driscoll C. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?. Biotechnol Adv 2011, 29:402-417.
37. Guo J., Cheng W.P., Gu J., Ding C., Qu X., Yang Z., et al. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-l-lysine nanocarrier to suppress prostate cancer growth in mice. Eur J Pharm Sci 2012, 45:521-532.
38. Guo J., Ogier J.R., Desgranges S., Darcy R., O'Driscoll C. Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials 2012, 33:7775-7784.
39. Guo J., Evans J.C., O'Driscoll C.M. Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer?. Trends Mol Med 2013, 19:250-261.
40. Hansel T.T., Kropshofer H., Singer T., Mitchell J.A., George A.J. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010, 9:325-338.
41. Hatlen M.A., Wang L., Nimer S.D. AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches. Front Med 2012, 6:248-262.
42. He W., Bennett M.J., Luistro L., Carvajal D., Nevins T., Smith M., et al. Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability. Mol Ther 2014, 22:359-370.
43. Heidenreich O., Krauter J., Riehle H., Hadwiger P., John M., Heil G., et al. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 2003, 101:3157-3163.
44. Hoffbrand A.V., Moss P.A.H. Essential haematology 2011, Wiley: Wiley-Blackwell.
45. Hossain D.M., Dos Santos C., Zhang Q., Kozlowska A., Liu H., Gao C., et al. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood 2014, 123:15-25.
46. Hou K.K., Pan H., Ratner L., Schlesinger P.H., Wickline S.A. Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. ACS Nano 2013, 7:8605-8615.
47. Huang X., Schwind S., Yu B., Santhanam R., Wang H., Hoellerbauer P., et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res 2013, 19:2355-2367.
48. Hubbell J.A., Langer R. Translating materials design to the clinic. Nat Mater 2013, 12:963-966.
49. Hutvagner G., Simard M.J., Mello C.C., Zamore P.D. Sequence-specific inhibition of small RNA function. PLoS Biol 2004, 2:E98.
50. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006, 6:714-727.
51. Ishida T., Ichihara M., Wang X., Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Control Release 2006, 115:243-250.
52. Ishikawa H., Nakamura Y., Jo J., Tabata Y. Gelatin nanospheres incorporating siRNA for controlled intracellular release. Biomaterials 2012, 33:9097-9104.
53. Janne P.A., Gray N., Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009, 8:709-723.
54. Jin Y., Liu S., Yu B., Golan S., Koh C.G., Yang J., et al. Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia. Mol Pharm 2010, 7:196-206.
55. Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 2011, 6:715-728.
56. Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siRNA therapeutics. Nat Mater 2013, 12:967-977.
57. Kantarjian H.M., Hochhaus A., Saglio G., De Souza C., Flinn I.W., Stenke L., et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011, 12:841-851.
58. Keane N., Freeman C., Swords R., Giles F.J. Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia. Expert Rev Hematol 2013, 6:9-24.
59. Koldehoff M., Elmaagacli A.H. Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia. Methods Mol Biol 2009, 487:451-466.
60. Konopleva M.Y., Jordan C.T. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011, 29:591-599.
61. Koren E., Torchilin V.P. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 2012, 18:385-393.
62. Kumar A., Zhang X., Liang X.J. Gold nanoparticles: emerging paradigm for targeted drug delivery system. Biotechnol Adv 2013, 31:593-606.
63. Lacerda L., Herrero M.A., Venner K., Bianco A., Prato M., Kostarelos K. Carbon-nanotube shape and individualization critical for renal excretion. Small 2008, 4:1130-1132.
64. Lambert G.K., Duhme-Klair A.K., Morgan T., Ramjee M.K. The background, discovery and clinical development of BCR-ABL inhibitors. Drug Discov Today 2013, 18:992-1000.
65. Landry B., Aliabadi H.M., Samuel A., Gul-Uludaq H., Jiang X., Kutsch O., et al. Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines. PLoS One 2012, 7:e44197.
66. Lee J.B., Hong J., Bonner D.K., Poon Z., Hammond P.T. Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater 2012, 11:316-322.
67. Lee J., Yun K.S., Choi C.S., Shin S.H., Ban H.S., Rhim T., et al. T Cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles. Bioconjug Chem 2012, 1174-1180.
68. Lee S.J., Son S., Yhee J.Y., Choi K., Kwon I.C., Kim S.H., et al. Structural modification of siRNA for efficient gene silencing. Biotechnol Adv 2013, 31:491-503.
69. Lee C.S., Park W., Park S.J., Na K. Endolysosomal environment-responsive photodynamic nanocarrier to enhance cytosolic drug delivery via photosensitizer-mediated membrane disruption. Biomaterials 2013, 34:9227-9236.
70. Liu J., Huang Y., Kumar A., Tan A., Jin S., Mozhi A., et al. pH-Sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv 2014, 32:693-710.
71. Livshits G., Lowe S.W. Accelerating cancer modeling with RNAi and nongermline genetically engineered mouse models. Cold Spring Harb Protoc 2013, 10.1101/pdb.top069856.
72. Lo-Coco F., Avvisati G., Vignetti M., Thiede C., Orlando S.M., Iacobelli S., et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013, 369:111-121.
73. Maciulaitis R., D'Apote L., Buchanan A., Pioppo L., Schneider C.K. Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive. Mol Ther 2012, 20:479-482.
74. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2011, 30:1009-1019.
75. Mann A.P., Tanaka T., Somasunderam A., Liu X., Gorenstein D.G., Ferrari M. E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater 2011, 23:H278-H282.
76. Matokanovic M., Barisic K., Filipovic-Grcic J., Maysinger D. Hsp70 silencing with siRNA in nanocarriers enhances cancer cell death induced by the inhibitor of Hsp90. Eur J Pharm Sci 2013, 50:149-158.
77. McCarthy J., O'Neill M.J., Bourre L., Walsh D., Quinlan A., Hurley G., et al. Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system. J Control Release 2013, 168:28-34.
78. Mintzer M.A., Simanek E.E. Nonviral vectors for gene delivery. Chem Rev 2009, 109:259-302.
79. Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y., et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 1993, 12:2715-2721.
80. Moghimi S.M. Exploiting bone marrow microvascular structure for drug delivery and future therapies. Adv Drug Deliv Rev 1995, 17:61-73.
81. Moghimi S.M., Hunter A.C., Andresen T.L. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 2012, 52:481-503.
82. Muntean A.G., Hess J.L. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol 2012, 7:283-301.
83. Nagasawa T. Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol 2006, 6:107-116.
84. Naito Y., Ui-Tei K. Designing functional siRNA with reduced off-target effects. Methods Mol Biol 2013, 942:57-68.
85. Nasrolahi Shirazi A., Tiwari R., Chhikara B.S., Mandal D., Parang K. Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs. Mol Pharm 2013, 10:488-499.
86. Nwajei F., Konopleva M. The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv Hematol 2013, 2013:953982.
87. Omedes Pujol M., Coleman D.J., Allen C.D., Heidenreich O., Fulton D.A. Determination of key structure-activity relationships in siRNA delivery with a mixed micelle system. J Control Release 2013, 172:939-945.
88. Ommen H.B., Hokland P., Haferlach T., Abildgaard L., Alpermann T., Haferlach C., et al. Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene. Br J Haematol 2014, 165:618-628.
89. Orfali N., McKenna S.L., Cahill M.R., Gudas L.J., Mongan N.P. Retinoid receptor signaling and autophagy in acute promyelocytic leukemia. Exp Cell Res 2014, 324:1-12.
90. Ozpolat B., Sood A.K., Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 2014, 66:110-116.
91. Park H., Tsutsumi H., Mihara H. Cell penetration and cell-selective drug delivery using α-helix peptides conjugated with gold nanoparticles. Biomaterials 2013, 34:4872-4879.
92. Popat U.R., Abraham J. Leukemia (Emerging cancer therapeutics) 2011, Demos Medical Publishing.
93. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013, 19:1423-1437.
94. Rothdiener M., Muller D., Castro P.G., Scholz A., Schwemmlein M., Fey G., et al. Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. J Control Release 2010, 44:251-258.
95. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. J Control Release 2010, 145:182-195.
96. Sahay G., Querbes W., Alabi C., Eltoukhy A., Sarkar S., Zurenko C., et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 2013, 31:653-658.
97. Salvana E.M., Salata R.A. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 2009, 22:274-290.
98. Salvati A., Pitek A.S., Monopoli M.P., Prapainop K., Bombelli F.B., Hristov D.R., et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013, 8:137-143.
99. Sanchez P.V., Perry R.L., Sarry J.E., Perl A.E., Murphy K., Swider C.R., et al. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 2009, 23:2109-2117.
100. Schellekens H., Hennink W.E., Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res 2013, 30:1729-1734.
101. Schneider C.K., Salmikangas P., Jilma B., Flamion B., Todorova L.R., Paphitou A., et al. Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 2010, 9:195-201.
102. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat Rev Cancer 2012, 12:278-287.
103. Shahin M., Soudy R., Aliabadi H.M., Keteman N., Kaur K., Lavasanifar A. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity. Biomaterials 2013, 34:4089-4097.
104. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004, 101:5328-5335.
105. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
106. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
107. Sipkins D.A., Wei X., Wu J.W., Runnel J.M., Cote D., Means T.K., et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005, 435:969-973.
108. Sou K., Goins B., Takeoka S., Tsuchida E., Phillips W.T. Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo. Biomaterials 2007, 28:2655-2666.
109. Sou K., Goins B., Leland M.M., Tsuchida E., Phillips W.T. Bone marrow-targeted liposomal carriers: a feasibility study in nonhuman primates. Nanomedicine (Lond) 2010, 5:41-49.
110. Sou K., Goins B., Oyajobi B.O., Travi B.L., Phillips W.T. Bone marrow-targeted liposomal carriers. Expert Opin Drug Deliv 2011, 8:317-328.
111. Stefater J.A., Ren S., Lang R.A., Duffield J.S. Metchnikoff's policemen: macrophages in development, homeostasis and regeneration. Trends Mol Med 2011, 17:743-752.
112. Steinchen S.D., Caldorera-Moore M., Peppas N.A. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 2012, 48:416-427.
113. Strumberg D., Schultheis B., Traugott U., Vank C., Santel A., Keil O., et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther 2012, 50:76-78.
114. Tabernero J., Shapiro G.I., LoRusso P.M., Cervantes A., Schwartz G.K., Weiss G.J., et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013, 3:406-417.
115. Tari A.M., Gutierrez-Puente Y., Monaco G., Stephens C., Sun T., Rosenblum M., et al. Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts 2007, 31:1243-1250.
116. Tentler J.J., Tan A.C., Weekes C.D., Jimeno A., Leong S., Pitts T.M., et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012, 9:338-350.
117. Ter Elst A., Ma B., Scherpen F.J., de Jonge H.J., Douwes J., Wierenga A.T., et al. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia. Cancer Res 2011, 71:2761-2771.
118. Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003, 4:346-358.
119. Thomas M., Gessner A., Vornlocher H.P., Hadwiger P., Greil J., Heidenreich O. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood 2005, 106:3559-3566.
120. Toffalini F., Kallin A., Vandenberghe P., Pierre P., Michaux L., Cools J., et al. The fusion proteins TEL-PDGFRβ and FIP1L1-PDGFRα escape ubiquitination and degradation. Haematologica 2009, 94:1085-1093.
121. Toriyabe N., Hayashi Y., Harashima H. The transfection activity of R8-modified nanoparticles and siRNA condensation using pH sensitive stearylated-octahistidine. Biomaterials 2013, 34:1337-1343.
122. Travlos G.S. Normal structure, function, and histology of the bone marrow. Toxicol Pathol 2006, 34:548-565.
123. Valencia-Serna J., Gul-Uludag H., Mahdipoor P., Jiang X., Uludag H. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation. J Control Release 2013, 172:495-503.
124. van Asbeck A.H., Beyerle A., McNeill H., Bovee-Geurts P.H., Lindberg S., Verdurmen W.P., et al. Molecular parameters of siRNA - cell penetrating peptide nanocomplexes for efficient cellular delivery. ACS Nano 2013, 7:3797-3807.
125. Van Buul J.D., Mul F.P., van der Schoot C.E., Hordijk P.L. ICAM-3 activation modulates cell-cell contacts of human bone marrow endothelial cells. J Vasc Res 2004, 41:28-37.
126. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasma and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
127. Waehler R., Russell S.J., Curiel D.T. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007, 8:573-587.
128. Walters D.K., Stoffregen E.P., Heinrich M.C., Deininger M.W., Druker B.J. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood 2005, 105:2952-2954.
129. Wang Z., Liu G., Zheng H., Chen X. Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities. Biotechnol Adv 2014, 32:831-843.
130. Ward S.V., Sternsdorf T., Woods N.B. Targeting expression of the leukemogenic PML-RARα fusion protein by lentiviral vector-mediated small interfering RNA results in leukemic cell differentiation and apoptosis. Hum Gene Ther 2011, 22:1593-1598.
131. Wilda M., Fuchs U., Wossmann W., Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 2002, 21:5716-5724.
132. Wilson R.C., Doudna J.A. Molecular mechanisms of RNA interference. Annu Rev Biophys 2013, 42:217-239.
133. Wong N.C., Bhadri V.A., Maksimovic J., Parkinson-Bates M., Ng J., Craig J.M., et al. Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance. BMC Genomics 2014, 15:416.
134. Xue H.Y., Liu S., Wong H.L. Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine (Lond) 2014, 9:295-312.
135. Yang J., Liu H., Zhang X. Design, preparation and application of nucleic acid delivery carriers. Biotechnol Adv 2014, 32:804-817.
136. Yu B., Mao Y., Bai L.Y., Herman S.E., Wang X., Ramanunni A., et al. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood 2013, 121:136-147.
137. Yuan Y., Zhou L., Miyamoto T., Iwasaki H., Harakawa N., Hetherington C.J., et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A 2001, 98:10398-10403.
138. Zhang H., Luo J., Li Y., Henderson P.T., Wang Y., Wachsmann-Hogiu S., et al. Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomedicine 2012, 8:1116-1124.
139. Zhang Y., Wang Z., Gemeinhart R.A. Progress in microRNA delivery. J Control Release 2013, 172:962-974.
140. Zhang Q., Hossain D.M., Nechaev S., Kozlowska A., Zhang W., Liu Y., et al. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood 2013, 121:1304-1315.
141. Zimmerman E.I., Turner D.C., Buaboonnam J., Hu S., Orwick S., Roberts M.S., et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood 2013, 122:3607-3615.